Analysts who follow Cardiff Oncology Inc (CRDF) on average expect it to rise 102.23% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.
That average rating earns the stock an Analyst Ranking of 79, which means it ranks higher than 79 of stocks, based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With Cardiff Oncology Inc Stock Today?
Cardiff Oncology Inc (CRDF) stock is trading at $12.98 as of 2:59 PM on Tuesday, Feb 2, a rise of $1.18, or 9.97% from the previous closing price of $11.80. The stock has traded between $11.57 and $13.34 so far today. Volume today is above average. So far 3,550,385 shares have traded compared to average volume of 2,421,802 shares.
Click Here to get the full report on Cardiff Oncology Inc (CRDF) Stock.
